Trial shows nearly one-third reduction in invasive disease progression or distant recurrence at follow-up
TUESDAY, Dec. 16, 2025 (HealthDay News) – Giredestrant, a selective estrogen receptor antagonist and degrader given as an adjuvant therapy, shows significant improvement in invasive disease-free survival (iDFS) in patients with early-stage, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, according to a study presented at the annual San Antonio Breast Cancer Symposium, held from Dec. 9 to 12 in San Antonio.
Aditya Bardia, M.D., M.P.H., from the University of California Los Angeles, and colleagues conducted a global, randomized, open-label trial in which 4,170 patients with HR-positive, HER2-negative early breast cancer (stages I to III) were assigned (1:1) to receive either 30 mg of oral giredestrant daily or one of four standard-of-care endocrine therapies (tamoxifen, letrozole, anastrozole, or exemestane). All patients received surgery and, if indicated, completed adjuvant or neoadjuvant chemotherapy.
The researchers report that after a median follow-up of 32.3 months, patients who received giredestrant had significantly better iDFS than those receiving standard-of-care endocrine therapy and were 30 percent less likely to develop invasive disease progression at follow-up. Additionally, patients who received giredestrant were 31 percent less likely than those in the standard-of-care arm to experience distant recurrence at follow-up. Overall survival data were immature but showed a positive trend in favor of giredestrant.
“Giredestrant demonstrated clinically meaningful superiority to currently well-established standard-of-care endocrine agents: aromatase inhibitors and tamoxifen,” Bardia said in a statement. “What is particularly striking and relevant is early separation of [the overall survival] curves.”
Several authors disclosed financial ties to pharmaceutical companies, including F. Hoffmann-La Roche, which manufactures giredestrant and funded the study.
Teen Girls" Recreational Physical Activity Linked to Breast Tissue Composition, Oxidative Stress 
Psychological Distress Quantified in Those With Unscheduled C-Section 
N-AVD Yields High Progression-Free Survival in Teens With Hodgkin Lymphoma 
One Year of Abatacept Delays Progression to RA for Up to Four Years in At-Risk Population 
Recommendations Developed for Optimizing Biologics in Adults With Severe Asthma 
Color Vision Deficiency Associated With Shorter Survival for Patients With Bladder Cancer 
Varenicline Can Cut Cannabis Use Among Men With Cannabis Use Disorder 
.jpg)
